New York, Jan 30, 2026, 14:53 ET — Regular session
- Boston Scientific shares climbed in afternoon trading, beating the broader U.S. market’s downturn
- The medical device company will release its earnings and hold a conference call on Feb. 4
- Investors are focused on news related to the Penumbra acquisition and what the 2026 outlook holds
Boston Scientific shares climbed 1.7% to $93.87 on Friday afternoon, rebounding from an earlier dip to $91.72.
The announcement arrives just days ahead of Boston Scientific’s fourth-quarter and full-year earnings report. The medical device maker plans to release results before the market opens on Feb. 4, followed by a conference call at 8 a.m. ET, featuring Mike Mahoney and Jon Monson. 1
This call marks the first major scheduled update since Boston Scientific struck a $14.5 billion cash-and-stock deal for Penumbra on Jan. 15, pricing the target at $374 a share. On the announcement call, Mahoney described the acquisition as a “home run,” Reuters reported. 2
Boston Scientific rose even as U.S. stocks dipped following Donald Trump’s announcement that he plans to nominate Kevin Warsh to replace Jerome Powell as Fed chair. “It’s hard to know exactly what direction Warsh will go,” said Eric Gerster, chief investment officer at AlphaCore Wealth Advisory. 3
Shares of other medical device makers like Abbott Laboratories, Medtronic and Stryker also moved higher during the session.
Boston Scientific’s Feb. 4 report will hinge on the 2026 demand outlook for its heart and vascular franchise, along with how recent deals might shift its short-term spending and cash flow priorities.
Investors are keen to hear specifics on the timing and financing structure of the Penumbra acquisition, along with how soon Boston Scientific expects it to boost earnings per share, a key measure of profitability.
That said, the outlook isn’t one-sided. Any cautious guidance, rising borrowing expenses, or hints of weaker procedure demand might drag on the stock, especially as the wider market reacts sharply to changes in interest-rate forecasts.
Boston Scientific will release its earnings before the bell on Feb. 4. Analysts will then get a chance to question management about the 2026 targets and how the company plans to finalize the Penumbra acquisition.
